Man Group plc Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Man Group plc acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,589 shares of the biopharmaceutical company's stock, valued at approximately $289,000.

A number of other large investors have also recently bought and sold shares of TGTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in TG Therapeutics by 3.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 92,683 shares of the biopharmaceutical company's stock worth $2,808,000 after purchasing an additional 2,890 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at about $4,515,000. Deutsche Bank AG grew its holdings in shares of TG Therapeutics by 40.4% during the fourth quarter. Deutsche Bank AG now owns 147,020 shares of the biopharmaceutical company's stock worth $4,425,000 after purchasing an additional 42,272 shares in the last quarter. Cornerstone Select Advisors LLC bought a new stake in TG Therapeutics during the fourth quarter valued at approximately $1,904,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of TG Therapeutics during the 4th quarter valued at about $453,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 1.1%

Shares of TGTX traded down $0.39 during trading hours on Friday, reaching $35.32. 1,825,344 shares of the company traded hands, compared to its average volume of 2,979,020. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a market capitalization of $5.61 billion, a price-to-earnings ratio of -353.16 and a beta of 2.21. The company's fifty day moving average price is $37.40 and its two-hundred day moving average price is $34.45. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's quarterly revenue was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.07) EPS. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TGTX. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.